Personalis Earnings Call: Key Takeaways
Personalis presented interim Victory study data for NeXT Personal, demonstrating 96% pre-surgical sensitivity and 100% detection of colorectal cancer recurrences with significant lead-time advantages.
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Personalis, Inc. filings on SEC EDGAR ↗
Filing type
Alerts
Time
5 alerts with these filters
Personalis presented interim Victory study data for NeXT Personal, demonstrating 96% pre-surgical sensitivity and 100% detection of colorectal cancer recurrences with significant lead-time advantages.
Christopher M. Hall, CEO, sold 29,112 shares of Personalis, Inc. at $15.87 a share, worth $462K in total on Nov 3, 2026. Shares held after the trade: 199,415 (-12.7%).
Personalis reported Q3 2026 total revenue of $25.6 million, a significant increase from $14.5 million in the prior year, driven by growth in clinical test volume and population sequencing. The company ended the quarter with $190.6 million in cash and noted its pending merger with Tempus AI. Due to the pending acquisition, the company is no longer providing forward-looking financial guidance.
“These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians, and biopharma partners.”
Chris Hall, Chief Executive Officer of Personalis
Personalis, Inc. has entered into a definitive merger agreement to be acquired by Tempus AI, Inc. The company continues to report a history of losses and maintains significant customer concentration with Moderna, the VA MVP, and Merck while focusing on its partner-centric strategy for cancer testing services.
Personalis announced the expiration of the Hart-Scott-Rodino (HSR) Act waiting period regarding its pending acquisition by Tempus AI, Inc. The expiration of the antitrust waiting period satisfies a key closing condition for the merger, which was originally announced on July 20, 2026. The transaction remains subject to approval by Personalis stockholders and other customary closing conditions.